QuidelOrtho Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Brian Blaser

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

CEO

Brian Blaser (59 yo)

less than a year

Tenure

Mr. Brian J. Blaser serves as CEO & President at QuidelOrtho Corporation since May 06, 2024 & serves as it's Director since May 15, 2024. He served as an Independent Director at Quanterix Corporation since...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Joseph Busky	Chief Financial Officer	2.5yrs	US$2.94m	0.018% € 410.0k
Robert Bujarski	Executive VP & COO	4.2yrs	US$3.41m	0.067% € 1.5m
Werner Kroll	Executive Officer	10.5yrs	US$2.03m	0.054% € 1.2m
Michael Iskra	Executive VP & Chief Commercial Officer	less than a year	US$3.32m	0.025% € 572.1k
Brian Blaser	President	less than a year	geen gegevens	geen gegevens
Jonathan Siegrist	Executive VP of Research & Development and CTO	less than a year	geen gegevens	geen gegevens
Juliet Cunningham	Vice President of Investor Relations	1.2yrs	geen gegevens	geen gegevens
Michelle Hodges	Senior VP	3.9yrs	US$3.55m	0.025% € 567.5k
Ronald Bowman	Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
William Ferenczy	Point of Care Business Unit Leader	no data	geen gegevens	geen gegevens
Tamara Ranalli	Molecular Diagnostics Business Unit Leader	no data	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van QL1A wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Brian Blaser	President	less than a year	geen gegevens	geen gegevens
Ann Rhoads	Independent Director	4.3yrs	US$314.47k	0.012% € 279.5k
Kenneth Widder	Independent Director	10yrs	US$320.47k	0.042% € 978.4k
Kenneth Buechler	Independent Non-Executive Chairman	17yrs	US$411.50k	0.13% € 3.0m
Edward Michael	Independent Director	5.9yrs	US$326.94k	0.023% € 539.7k
Mary Polan	Independent Director	31.8yrs	US$300.95k	0.035% € 807.8k
Evelyn Dilsaver	Independent Director	2.5yrs	US$286.95k	0.0077% € 179.1k
Matthew Strobeck	Independent Director	6.6yrs	US$280.00k	0.044% € 1.0m
Robert Schmidt	Independent Director	2.5yrs	US$70.00k	geen gegevens
Joseph Wilkins	Independent Director	3.8yrs	US$280.00k	0.0098% € 226.1k
James Prutow	Independent Director	less than a year	US$110.83k	0.0023% € 52.2k

4.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van QL1A wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

QuidelOrtho Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Quidelortho Corporation Announces Executive Changes

QuidelOrtho Corporation Appoints Jonathan Siegrist, PhD, as New Executive Vice President of Research and Development and Chief Technology Officer

QuidelOrtho Corporation Appoints Lee Bowman as Chief Human Resources Officer

QuidelOrtho Corporation Announces CEO Changes

QuidelOrtho Corporation Announces CEO Changes

QuidelOrtho Corporation Announces CEO Changes

Recent updates

Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.19 loss in 3Q 2023)

Quidelortho Corporation Announces Executive Changes

QuidelOrtho Corporation to Report Q3, 2024 Results on Nov 07, 2024

QuidelOrtho Corporation Appoints Jonathan Siegrist, PhD, as New Executive Vice President of Research and Development and Chief Technology Officer

QuidelOrtho Corporation Appoints Lee Bowman as Chief Human Resources Officer

QuidelOrtho Corporation(NasdaqGS:QDEL) dropped from S&P 400

QuidelOrtho Corporation to Report Q2, 2024 Results on Jul 31, 2024

QuidelOrtho Corporation Suspends Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$25.50 loss per share (vs US$0.73 profit in 1Q 2023)

QuidelOrtho Corporation Announces CEO Changes

QuidelOrtho Corporation to Report Q1, 2024 Results on May 08, 2024

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

QuidelOrtho Corporation Receives FDA 510(K) Clearance for its QuickVue COVID-19 Test

Full year 2023 earnings released: US$0.15 loss per share (vs US$9.66 profit in FY 2022)

QuidelOrtho Corporation Announces CEO Changes

QuidelOrtho Corporation Announces CEO Changes

New minor risk - Share price stability

QuidelOrtho Corporation Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$0.15 loss per share (vs US$9.66 profit in FY 2022)

QuidelOrtho Corporation to Report Q4, 2023 Results on Feb 13, 2024

QuidelOrtho Corporation Provides Revenue Guidance for the Year 2023

QuidelOrtho Corporation Receives 510(K) Clearance for Savanna(R) Multiplex Molecular Platform and Savanna(R) HSV 1+2/VZV PCR Assay

QuidelOrtho Corporation Announces Board Changes

Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.29 profit in 3Q 2022)

QuidelOrtho Corporation Provides Earnings Guidance for the Year 2023

QuidelOrtho Corporation to Report Q3, 2023 Results on Nov 01, 2023

QuidelOrtho Corporation Receives CLIA Waiver for Sofia 2 SARS Antigen+ FIA

QuidelOrtho Corporation Announces Resignation of Christopher M. Smith from the Board, Effective August 31, 2023

QuidelOrtho Corporation Revises Earnings Guidance for the Year 2023

New major risk - Financial position

Second quarter 2023 earnings released: US$0.80 loss per share (vs US$0.37 profit in 2Q 2022)

QuidelOrtho Corporation to Report Q2, 2023 Results on Aug 08, 2023

QuidelOrtho Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings released: EPS: US$0.73 (vs US$11.46 in 1Q 2022)

Full year 2022 earnings released: EPS: US$9.66 (vs US$16.74 in FY 2021)

QuidelOrtho Corporation Provides Financial Guidance for the Fiscal Year 2023

QuidelOrtho Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended January 1, 2023

QuidelOrtho Corporation Announces Health Canada Grants License for Quidel TriageTrue High-Sensitivity Troponin I Test to Aid in the Diagnosis of Myocardial Infarction

Investor sentiment deteriorated over the past week

QuidelOrtho Corporation Announces Executive Changes

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.29 (vs US$5.17 in 3Q 2021)

QuidelOrtho Corporation to Report Q3, 2022 Results on Nov 02, 2022

QuidelOrtho Corporation (NasdaqGS:QDEL) announces an Equity Buyback for $300 million worth of its shares.

Second quarter 2022 earnings released: EPS: US$0.37 (vs US$0.46 in 2Q 2021)

QuidelOrtho Corporation to Report Q2, 2022 Results on Aug 04, 2022

Investor sentiment improved over the past week

QuidelOrtho Corporation(NasdaqGS:QDEL) dropped from Russell 2500 Growth Index

High number of new directors

High number of new directors

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd